Background and aims: The transcription factor NF-κB has risen as a promising target for anti-inflammatory therapeutics. In the liver, however, NF-κB inhibition mediates both damaging and protective effects. The outcome is deemed to depend on the liver cell type addressed. Recent gene knock-out studies focused on the role of NF-κB in hepatocytes, whereas the role of NF-κB in Kupffer cells has not yet been investigated in vivo. We here present a novel approach, which may be suitable for clinical application, to selectively target NF-κB in Kupffer cells and analyze the effects in experimental models of liver injury.
Methods: NF-κB inhibiting decoy oligodeoxynucleotides were loaded upon gelatin nanoparticles (D-NP) and their in vivo distribution was determined by confocal microscopy. Liver damage, NF-κB activity, cytokine levels and apoptotic protein expression were evaluated after LPS, GalN/LPS, or Concanavalin A challenge and partial warm ischemia and subsequent reperfusion, respectively.
Results: D-NP were selectively taken up by Kupffer cells and inhibited NF-κB activation. Inhibition of NF-κB in Kupffer cells improved survival and reduced liver injury after GalN/LPS as well as after ConA challenge. While antiapoptotic protein expression in liver tissue was not reduced, pro-apoptotic players such as JNK were inhibited. In contrast, selective inhibition of NF-κB augmented reperfusion injury.
Conclusions: NF-κB inhibiting decoy oligodeoxynucleotide loaded gelatin nanoparticles are a novel tool to selectively inhibit NF-κB activation in Kupffer cells in vivo. Thus, liver injury can be reduced in experimental fulminant hepatitis, but increased at ischemia/reperfusion.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.